- Home
- KIO vs AUTL Comparison
KIO vs AUTL Comparison
Compare KIO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIO
- AUTL
- Stock Information
- Founded
- KIO 2011
- AUTL 2014
- Country
- KIO United States
- AUTL United Kingdom
- Employees
- KIO 2400
- AUTL N/A
- Industry
- KIO Investment Managers
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KIO Finance
- AUTL Health Care
- Exchange
- KIO Nasdaq
- AUTL Nasdaq
- Market Cap
- KIO 522.7M
- AUTL 625.4M
- IPO Year
- KIO N/A
- AUTL 2018
- Fundamental
- Price
- KIO $12.46
- AUTL $1.65
- Analyst Decision
- KIO
- AUTL Strong Buy
- Analyst Count
- KIO 0
- AUTL 5
- Target Price
- KIO N/A
- AUTL $9.12
- AVG Volume (30 Days)
- KIO 136.5K
- AUTL 2.8M
- Earning Date
- KIO 01-01-0001
- AUTL 08-12-2025
- Dividend Yield
- KIO 10.82%
- AUTL N/A
- EPS Growth
- KIO N/A
- AUTL N/A
- EPS
- KIO N/A
- AUTL N/A
- Revenue
- KIO N/A
- AUTL $29,934,000.00
- Revenue This Year
- KIO N/A
- AUTL $472.28
- Revenue Next Year
- KIO N/A
- AUTL $114.92
- P/E Ratio
- KIO N/A
- AUTL N/A
- Revenue Growth
- KIO N/A
- AUTL 185.17
- 52 Week Low
- KIO $10.52
- AUTL $1.11
- 52 Week High
- KIO $13.59
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- KIO 44.51
- AUTL 33.78
- Support Level
- KIO $12.26
- AUTL $1.70
- Resistance Level
- KIO $12.70
- AUTL $1.81
- Average True Range (ATR)
- KIO 0.10
- AUTL 0.15
- MACD
- KIO -0.04
- AUTL -0.05
- Stochastic Oscillator
- KIO 38.60
- AUTL 14.41
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.